Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2020

Schedule of diluted income (loss) per share

The following table sets forth the potential common shares that could potentially dilute basic income per share in the future that were not included in the computation of diluted income (loss) per share because to do so would have been anti-dilutive for the periods presented:


	For the Three and Six Months Ended
	June 30,	June 30,
	2020	2019
Unvested restricted stock units/awards	1,221,575	1,150,162
Preferred shares	250,000	250,000
Total potential dilutive effect	1,471,575	1,400,162